A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Trial Profile

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Mar 2018 Results (n=9340) of post hoc analysis assessing myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy, were published in the American Journal of Cardiology.
    • 01 Feb 2018 Results evaluating risk of cardiovascular events from ELIXA, LEADER, SUSTAIN-6 and EXSCEL studies, published in the Annals of Pharmacotherapy.
    • 19 Dec 2017 Results assessing secondary analysis of cardiovascular outcomes, published in the Annals of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top